 Artist: Elefante: mp3 download Genre(s): Rock Elefante's discography:  Resplandor Year: 2007 Tracks: 11 Formed in the early '90s, Elefante had the chance to play for a major audience in 2000 patch opening for JoaquÃn Sabina at Mexico City's Auditorio Nacional. A year later, the lot delineated Mexico in Viña del Mar, the to the highest degree democratic Chilean fete, with a strain called "De la Noche a la Mañana." The song was featured in Elefante's debut album El Que Busca Encuentra, produced by Nacho Bejar. |
Wednesday 3 September 2008
Mp3 music: Elefante
Sunday 24 August 2008
Mp3 music: Alex Bueno
 Artist: Alex Bueno: mp3 download Genre(s): Latin: Dance Alex Bueno's discography:  Merengue Year: Tracks: 2  Bachata Year: Tracks: 6  Alex Bueno Year: Tracks: 4 Dominican Alex Bueno began singing and playing guitar at a identical thomas Young age. He moved from his aboriginal San José de las Matas to Santo Domingo when he was a adolescent, looking at for a better fortune to get convoluted in point byplay. In 1979, the whitney Young creative soul linked Gerardo Vera's All-Stars, subsequently transcription a local hit called "Piel Canela" with Fernando Villalona. In 1982, Alex Bueno formed a tropical play called Orquesta Liberación, singing along with Andrés de Jesus. After issue 1993's Ternura, the successful record album Me Equivoque was recorded and produced in 1995 by Jaime Querol and Manuel Tejada. Following 1999's Corazón Duro and Bachata A Su Tiempo, Alex Bueno returned in 2001 with Unicamente Tú, the title was based on a popular song composed by Felipe Valdes. |
Download Fler mp3
Thursday 14 August 2008
Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis Of Viprinex(TM) Phase 3 Stroke Trials
�Neurobiological
Technologies, Inc. (NTI(R)) (Nasdaq: NTII) announced that enrollment
into its deuce Phase 3 pivotal studies evaluating Viprinex(TM) (ancrod) for
the discussion of acute ischemic stroke has reached the layer of patients
necessary to conduct a planned interim analysis crosswise the two studies. NTI
is presently studying whether Viprinex is safe and effective for treating
acute ischemic stroke when given within six-spot hours of stroke onset.
"We ar very pleased to experience reached the enrollment criteria to lead
the aforethought interim analysis," stated Paul E. Freiman, president and chief
executive officer of NTI. "Our independent Data Safety Monitoring Board
(DSMB) will meet to limited review the efficaciousness data on an unblinded basis for the
first time. In addition, the DSMB volition evaluate the safety of Viprinex, as
they've been doing since the startle of the studies."
Results of the interim analysis are expected in January 2009. The
interim analysis will be based on the first 500 tempered patients in the
stream trials wHO have completed their 90 day judgment. If the treatment
effect observed for the ancrod patients is not bettor than that observed
for the placebo patients, then the trials will be halted for futility,
indicating that they are unlikely to attest the benefit required for
approval. If the trials are allowed to continue, NTI testament not experience access
to any unblinded patient information until the trials ar completed. The primary
termination of the trials is the modified Rankin Score, a quantity of
disablement.
"We believe that data from five hundred patients is sufficient for the DSMB to
comport a thorough assessment of futility, and have consequently moved up
the meantime analysis from earlier plans to conduct it at 650 patients,"
stated Warren W. Wasiewski, M.D., vice president and chief medical officer.
"This is a significant milestone for the program and we are all look
forward to learning the outcome of this review."
About Ischemic Stroke
Ischemic accident is caused by obstruction of a blood vessel in the brain
referable to a clot. The lack of blood flow, or ischemia, leads to cell death.
According to the American Heart Association, 87% of the 700,000 yearly
strokes in the United States are ischemic. Stroke is the third preeminent
cause of death in the United States, behind heart disease and cancer, and
the leading cause of handicap. The only FDA-approved do drugs for the
treatment of acute ischemic stroke is Activase(R) (alteplase), which
presently must be given within three hours of stroke onset.
About Neurobiological Technologies, Inc.
Neurobiological Technologies, Inc., (Nasdaq: NTII) is a
biopharmaceutical company focussed on developing novel, first-in-class
agents for central nervous system atmospheric condition and former serious unmet
medical necessarily. The Company's most advanced product campaigner, Viprinex(TM)
(ancrod), is in Phase 3 clinical testing as a novel investigational drug
for the treatment of acute ischemic cerebrovascular accident. Viprinex has multiple
mechanisms of action and is specifically designed to double the time period
that patients can buoy be treated after the onset of a stroke. Acute ischaemic
stroke is one of the about prevalent, debilitating and pricy diseases in
the humans for which there are few satisfactory treatment options. NTI too
has early-stage development programs for Alzheimer's and Huntington's
diseases and rights to receive payments on an approved dose for Alzheimer's
disease and an investigational drug in Phase 3 trials for brain swelling.
Forward Looking Statements
Except for the historical information contained herein, the matters
discussed in this press release are modern statements that involve
risks and uncertainties, including uncertainties regarding the outcome of
the interim analysis, obtaining approval for Viprinex, levels of future
expenditures and capital resources needed to fund trading operations, as well as
other risks elaborated from sentence to time in our filings with the Securities
and Exchange Commission, including our Annual Report on Form 10-K as
updated periodically in Quarterly Reports on Form 10-Q and Current Reports
on Form 8-K. Actual results whitethorn differ materially from those projected.
These forward-looking statements represent our judgment as of the date of
the release and we undertake no obligation to update these forward-looking
statements.
Neurobiological Technologies, Inc.
http://www.ntii.com
More info
Technologies, Inc. (NTI(R)) (Nasdaq: NTII) announced that enrollment
into its deuce Phase 3 pivotal studies evaluating Viprinex(TM) (ancrod) for
the discussion of acute ischemic stroke has reached the layer of patients
necessary to conduct a planned interim analysis crosswise the two studies. NTI
is presently studying whether Viprinex is safe and effective for treating
acute ischemic stroke when given within six-spot hours of stroke onset.
"We ar very pleased to experience reached the enrollment criteria to lead
the aforethought interim analysis," stated Paul E. Freiman, president and chief
executive officer of NTI. "Our independent Data Safety Monitoring Board
(DSMB) will meet to limited review the efficaciousness data on an unblinded basis for the
first time. In addition, the DSMB volition evaluate the safety of Viprinex, as
they've been doing since the startle of the studies."
Results of the interim analysis are expected in January 2009. The
interim analysis will be based on the first 500 tempered patients in the
stream trials wHO have completed their 90 day judgment. If the treatment
effect observed for the ancrod patients is not bettor than that observed
for the placebo patients, then the trials will be halted for futility,
indicating that they are unlikely to attest the benefit required for
approval. If the trials are allowed to continue, NTI testament not experience access
to any unblinded patient information until the trials ar completed. The primary
termination of the trials is the modified Rankin Score, a quantity of
disablement.
"We believe that data from five hundred patients is sufficient for the DSMB to
comport a thorough assessment of futility, and have consequently moved up
the meantime analysis from earlier plans to conduct it at 650 patients,"
stated Warren W. Wasiewski, M.D., vice president and chief medical officer.
"This is a significant milestone for the program and we are all look
forward to learning the outcome of this review."
About Ischemic Stroke
Ischemic accident is caused by obstruction of a blood vessel in the brain
referable to a clot. The lack of blood flow, or ischemia, leads to cell death.
According to the American Heart Association, 87% of the 700,000 yearly
strokes in the United States are ischemic. Stroke is the third preeminent
cause of death in the United States, behind heart disease and cancer, and
the leading cause of handicap. The only FDA-approved do drugs for the
treatment of acute ischemic stroke is Activase(R) (alteplase), which
presently must be given within three hours of stroke onset.
About Neurobiological Technologies, Inc.
Neurobiological Technologies, Inc., (Nasdaq: NTII) is a
biopharmaceutical company focussed on developing novel, first-in-class
agents for central nervous system atmospheric condition and former serious unmet
medical necessarily. The Company's most advanced product campaigner, Viprinex(TM)
(ancrod), is in Phase 3 clinical testing as a novel investigational drug
for the treatment of acute ischemic cerebrovascular accident. Viprinex has multiple
mechanisms of action and is specifically designed to double the time period
that patients can buoy be treated after the onset of a stroke. Acute ischaemic
stroke is one of the about prevalent, debilitating and pricy diseases in
the humans for which there are few satisfactory treatment options. NTI too
has early-stage development programs for Alzheimer's and Huntington's
diseases and rights to receive payments on an approved dose for Alzheimer's
disease and an investigational drug in Phase 3 trials for brain swelling.
Forward Looking Statements
Except for the historical information contained herein, the matters
discussed in this press release are modern statements that involve
risks and uncertainties, including uncertainties regarding the outcome of
the interim analysis, obtaining approval for Viprinex, levels of future
expenditures and capital resources needed to fund trading operations, as well as
other risks elaborated from sentence to time in our filings with the Securities
and Exchange Commission, including our Annual Report on Form 10-K as
updated periodically in Quarterly Reports on Form 10-Q and Current Reports
on Form 8-K. Actual results whitethorn differ materially from those projected.
These forward-looking statements represent our judgment as of the date of
the release and we undertake no obligation to update these forward-looking
statements.
Neurobiological Technologies, Inc.
http://www.ntii.com
More info
Wednesday 6 August 2008
Thou Art Lord
Artist: Thou Art Lord
Genre(s):
Rock: Sympho
Metal: Death,Black
Discography:
Dv8
Year: 2002
Tracks: 9
Diabolou Archaes Legeones
Year: 1994
Tracks: 2
Thou Art Lord is the experimental Rotting Christ vocalist/guitarist Sakis Tolis and Necromantia bassist the Magus. Formed in 1992 to explore the duo's enthrallment with everything fiendish, immorality, and black, Thou Art Lord's
Friday 27 June 2008
Bishop Of Hexen
Artist: Bishop Of Hexen
Genre(s):
Metal: Death,Black
Metal
Discography:
The Nightmarish Compositions
Year: 2006
Tracks: 10
Archives Of An Enchanted Philosophy
Year: 1997
Tracks: 8
Thursday 19 June 2008
Radiohead wants Prince cover on YouTube
Thom Yorke questions removal of videos
After word spread that Prince covered Radiohead's "Creep" at the Coachella festival, the tens of thousands who couldn't be there ran to YouTube for a peek. Everyone was quickly denied -- even Radiohead.
All videos of Prince's unique rendition of Radiohead's early hit were quickly taken down, leaving only a message that his label, NPG Records, had removed the clips, claiming a copyright violation. But the posted videos were shot by fans and, obviously, the song isn't Prince's.
In a recent interview, Thom Yorke said he heard about Prince's performance from a text message and thought it was "hilarious." Yorke laughed when his bandmate, guitarist Ed O'Brien, said the blocking had prevented even him from seeing Prince's version of their song.
"Really? He's blocked it?" asked Yorke, who figured it was their song to block or not. "Surely we should block it. Hang on a moment." Yorke added, "Well, tell him to unblock it. It's our ... song."
YouTube prohibits the posting of copyrighted material. If the site receives a complaint from a copyright owner, it will in most cases remove the video(s). Whether the same could be done for a company not holding a copyright is less clear, but Yorke's argument would seem to bear some credence according to YouTube's policies. YouTube, which is owned by Google, declined comment.
Prince has not responded to a request for comment.
The dispute was an interesting twist in debates over digital ownership, held between two major acts with differing views on music and the Internet. Radiohead famously released their most recent album, "In Rainbows," as a digital download with optional pricing. They also have a channel on YouTube.
When Prince performed at Coachella on April 26, he prohibited the standard arrangement of allowing photographers to shoot near the stage during the first three songs of his set. Instead, he had a camera crew filming his performance.
Prince, who founded NPG Records in 1993, has been innovative when it comes to music distribution, too. He released his 1997 album, "Crystal Ball," on the Internet and in 2006 was awarded a lifetime achievement award by the Webbys. In 2007, he gave away copies of his disc "Planet Earth" in a British Sunday newspaper.
But Prince has also shut down his official Web site and in September said he would sue YouTube and eBay for not filtering unauthorized content.
Prince fans have organized to urge him to relent in his legal fights to control images and photographs of himself. As of yesterday, the most popular YouTube clip about Prince playing "Creep" is an expletive-laden rant from Sam Conti Jr., who describes himself as a "former Prince fan."
After word spread that Prince covered Radiohead's "Creep" at the Coachella festival, the tens of thousands who couldn't be there ran to YouTube for a peek. Everyone was quickly denied -- even Radiohead.
All videos of Prince's unique rendition of Radiohead's early hit were quickly taken down, leaving only a message that his label, NPG Records, had removed the clips, claiming a copyright violation. But the posted videos were shot by fans and, obviously, the song isn't Prince's.
In a recent interview, Thom Yorke said he heard about Prince's performance from a text message and thought it was "hilarious." Yorke laughed when his bandmate, guitarist Ed O'Brien, said the blocking had prevented even him from seeing Prince's version of their song.
"Really? He's blocked it?" asked Yorke, who figured it was their song to block or not. "Surely we should block it. Hang on a moment." Yorke added, "Well, tell him to unblock it. It's our ... song."
YouTube prohibits the posting of copyrighted material. If the site receives a complaint from a copyright owner, it will in most cases remove the video(s). Whether the same could be done for a company not holding a copyright is less clear, but Yorke's argument would seem to bear some credence according to YouTube's policies. YouTube, which is owned by Google, declined comment.
Prince has not responded to a request for comment.
The dispute was an interesting twist in debates over digital ownership, held between two major acts with differing views on music and the Internet. Radiohead famously released their most recent album, "In Rainbows," as a digital download with optional pricing. They also have a channel on YouTube.
When Prince performed at Coachella on April 26, he prohibited the standard arrangement of allowing photographers to shoot near the stage during the first three songs of his set. Instead, he had a camera crew filming his performance.
Prince, who founded NPG Records in 1993, has been innovative when it comes to music distribution, too. He released his 1997 album, "Crystal Ball," on the Internet and in 2006 was awarded a lifetime achievement award by the Webbys. In 2007, he gave away copies of his disc "Planet Earth" in a British Sunday newspaper.
But Prince has also shut down his official Web site and in September said he would sue YouTube and eBay for not filtering unauthorized content.
Prince fans have organized to urge him to relent in his legal fights to control images and photographs of himself. As of yesterday, the most popular YouTube clip about Prince playing "Creep" is an expletive-laden rant from Sam Conti Jr., who describes himself as a "former Prince fan."
Friday 6 June 2008
Brad Pitt - Pitt Spends Big On Style
Stylish BRAD PITT's latest Swiss shopping spree has been exposed by website Eonline.com.
The movie hunk was a surprise shopper at Design Miami/Basel in Switzerland earlier this week (beg02Jun08), where he bought lamps, a table, chairs and a rug from various dealers.
The website reports Pitt spent more than $290,000 (GBP145,000) for a marble rococo-style table by Dutch designer Jeroen Verhoeven and $50,000 (GBP25,000) on two Bronze Poly Chairs by London-based Max Lamb.
See Also
Subscribe to:
Posts (Atom)